

Korea's Samyang Holdings Biopharma offers new filler for dermatologists

04 July 2022 | News

Safety and efficacy of Lafullen demonstrated in a 24-month study

Research results confirm the long-term safety and efficacy of the new Lafullen filler from South Korea-based Samyang Holdings Biopharmaceutical Division. A dermal filler is a safe and proven medical device that is injected into the subcutaneous fat layer of the skin to add volume and fill in facial wrinkles for a smoother, more youthful appearance.

Sam Kim, Head of the Biopharmaceutical Division of Samyang Holdings, said: "Scientific research has confirmed the duration of efficacy, safety and stability of Lafullen." He added: "The results of the study are being used to refine the treatment protocol to ensure the highest standards of safety and efficacy for use by national and international dermatologists."

The development of Lafullen, an injectable dermal filler from the biopharmaceutical division of Samyang Holdings, began in 2015 and received marketing approval from the Ministry of Food and Drug Safety in 2021. Lafullen is made of PCL (polycaprolactone), a material biodegradable polymer for medical use, as its main component. Using proprietary technology from Samyang Holdings Biopharmaceutical Division, Lafullen has less irritation compared to existing PCL fillers, and natural volume can be expected.